Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background

References

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34–47. 10.1126/science.3513311Search in Google Scholar

2. Goldstein JL, Hobbs H, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease, Vol II, 7th ed. New York: McGraw-Hill, 1995: 1981–2030. Search in Google Scholar

3. Villeger L, Abifadel M, Allard D, Rabés J-P, Thiart R, Kotze MJ, et al. The UMD-LDLR database: additions to the software and 490 new entries to the database. Hum Mutat 2002; 20: 81–7. 10.1002/humu.10102Search in Google Scholar

4. Heath KE, Gahan M, Whittall RA, Humphries S. Low-density lipoprotein receptor gene (LDL-R) world-wide website in familial hypercholesterolemia: update, new features and mutation analysis. Atherosclerosis 2001; 154: 243–6. 10.1016/S0021-9150(00)00647-XSearch in Google Scholar

5. Ward AJ, O'Kane M, Nicholls DP, Young IS, Nevin NC, Graham CA. A novel single base deletion in the LDLR gene (211delG): effect on serum lipid profiles and the influence of other genetic polymorphism in the ACE gene, apoE and apoB genes. Atherosclerosis 1996; 120: 83–91. 10.1016/0021-9150(95)05685-8Search in Google Scholar

6. Uiterwaal CS, Witterman JC, De Brujin AM, Hofman A, Grobbee DE. Families and natural history of lipids in childwood: an 18year follow up study. Am J Epidemiol 1997; 145: 777–85. 10.1093/oxfordjournals.aje.a009170Search in Google Scholar

7. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP), expert panel on detection evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486–97. 10.1001/jama.285.19.2486Search in Google Scholar

8. Pimstone SN, Defesche JC, Clee SM, Bakker HD, Hayden MR, Kastelein JJ. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 826–33. 10.1161/01.ATV.17.5.826Search in Google Scholar

9. Hansen PS, Defesche JC, Kastelein JJ, Fraza L, Gerdes C, Tato F, et al. Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries. Arterioscler Thromb Vasc Biol 1997; 17: 741–7. 10.1161/01.ATV.17.4.741Search in Google Scholar

10. Gaffney D, Forster L, Caslake MJ, Bedford D, Stewart JP, Stewart G, et al. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia. Atherosclerosis 2002; 162: 33–43. 10.1016/S0021-9150(01)00679-7Search in Google Scholar

11. Defesche JC, Pricker KL, Hayden MR, van der Ende BE, Kastelein JJ. Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Arch Intern Med 1993; 153: 2349–56. 10.1001/archinte.1993.00410200071008Search in Google Scholar

12. Raal FJ, Pilcher G, Rubinsztein DC, Lingenhel A, Utermann G. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. Atherosclerosis 1997; 129: 97–102. 10.1016/S0021-9150(96)06007-8Search in Google Scholar

13. Schneider WJ, Slaughter CJ, Goldstein JL, Anderson RG, Capra JD, Brown MS. Use of antipeptide antibodies to demonstrate external orientation of the NH2-terminus of the low density lipoprotein receptor in the plasma membrane of fibroblasts. J Cell Biol 1983; 97: 1635–40. 10.1083/jcb.97.5.1635Search in Google Scholar

14. Tolleshaug H, Goldstein JL, Schneider WJ, Brown MS. Posttranslational processing of the LDL receptor and its genetic disruption in familial hypercholesterolemia. Cell 1982; 30: 715–24. 10.1016/0092-8674(82)90276-8Search in Google Scholar

15. Cummings RD, Kornfeld S, Schneider WJ, Hobgood KK, Tolleshaug H, Brown MS, et al. Biosynthesis of N- and O-linked oligosaccharides of the low density lipoprotein receptor. J Biol Chem 1983; 258: 15261–73. 10.1016/S0021-9258(17)43802-6Search in Google Scholar

16. Pastan MS, Willingham MC. Receptor-mediated endocytosis: coated pits receptosomes and the Golgi. Trends Biochem Sci 1983; 8: 250–4. 10.1016/0968-0004(83)90351-1Search in Google Scholar

17. Maxfield FR. Weak bases and ionophores rapidly and reversibly raise the pH of endocytic vesicles in cultured mouse fibroblasts. J Cell Biol 1982; 95: 676–81. 10.1083/jcb.95.2.676Search in Google Scholar

18. Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39: 27–38. 10.1016/0092-8674(84)90188-0Search in Google Scholar

19. Francke U, Brown MS, Goldstein JL. Assignment of the human gene for the low density lipoprotein receptor to chromosome 19: synteny of a receptor, a ligand, and a genetic disease. Proc Natl Acad Sci USA 1984; 81: 2826–30. 10.1073/pnas.81.9.2826Search in Google Scholar PubMed PubMed Central

20. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, et al. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860–921. 10.1038/35057062Search in Google Scholar PubMed

21. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291: 1304–51. 10.1126/science.1058040Search in Google Scholar PubMed

22. Sudhof TC, Goldstein JL, Brown MS, Russell DW. The LDL receptor gene: a mosaic of exons shared with different proteins. Science 1985; 228: 815–22. 10.1126/science.2988123Search in Google Scholar

23. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990; 24: 133–70. 10.1146/annurev.ge.24.120190.001025Search in Google Scholar

24. Esser V, Limbird LE, Brown MS, Goldstein JL, Russell DW. Mutational analysis of the ligand binding domain of the low density lipoprotein receptor. J Biol Chem 1988; 263: 13282–90. 10.1016/S0021-9258(18)37702-0Search in Google Scholar

25. Leitersdorf E, Hobbs HH, Fourie AM, Jacobs M, van der Westhuyzen DR, Coetzee GA. Deletion in the first cysteine-rich repeat of low density lipoprotein receptor impairs its transport but not lipoprotein binding in fibroblasts from a subject with familial hypercholesterolemia. Proc Natl Acad Sci USA 1988; 85: 7912–6. 10.1073/pnas.85.21.7912Search in Google Scholar

26. Lehrman MA, Goldstein JL, Brown MS, Russell DW, Schneider WJ. Internalization-defective LDL receptors produced by genes with nonsense and frameshift mutations that truncate the cytoplasmic domain. Cell 1985; 41: 735–43. 10.1016/S0092-8674(85)80054-4Search in Google Scholar

27. Leitersdorf E, Van der Westhuyzen DR, Coetzee GA, Hobbs HH. Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners. J Clin Invest 1989; 84: 954–61. 10.1172/JCI114258Search in Google Scholar

28. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445–66. 10.1002/humu.1380010602Search in Google Scholar

29. Bertolini S, Cassanelli R, Garuti M, Ghisellini M, Simone ML, Rolleri M, et al. Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999; 19: 408–18. 10.1161/01.ATV.19.2.408Search in Google Scholar

30. Endo A, Tsujita Y, Kuroda M, Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 1977; 77: 31–6. 10.1111/j.1432-1033.1977.tb11637.xSearch in Google Scholar

31. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001; 88: 270–4. 10.1016/S0002-9149(01)01639-3Search in Google Scholar

32. Caslake MJ, Stewart G, Day S, Daly E, Nwose EM, Chapman MJ, et al. Rosuvastatin normalises atherogenic levels of ApoB-containing lipoprotein subfractions. Int J Clin Pract 2002; 124: 8. Search in Google Scholar

33. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 2002; 164: 129–45. 10.1016/S0021-9150(02)00052-7Search in Google Scholar

34. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 2002; 160: 41–8. 10.1016/S0021-9150(01)00544-5Search in Google Scholar

35. Prassl R, Caslake MJ, Packard CJ, Palmer MK, Chapman JM. Rosuvastatin enhances lipid fluidity in atherogenic Apo-B containing lipoproteins. Atheroscler Suppl 2002; 3: 187. 10.1016/S1567-5688(02)80562-1Search in Google Scholar

36. Asztalos BF, Horvath KV, McNamara JR, Roheim PR, Rubinstein JJ, Schaefer EJ. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002; 164: 361–9. 10.1016/S0021-9150(02)00149-1Search in Google Scholar

37. Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002; 20: 303–28. 10.1111/j.1527-3466.2002.tb00099.xSearch in Google Scholar

38. Sanguigni V, Pignatelli P, Caccese D, Pulcinelli FM, Lenti L, Magnaterra R, et al. Atorvastatin decreases platelet superoxide anion production in hypercholesterolemic patients. Eur Heart J 2002; 4: 372. Search in Google Scholar

39. Li W, Asagami T, McTaggart F, Tsao P. Rosuvastatin inhibits monocyte/endothelial interactions in APOE (−/−) mice. Int J Clin Pract 2002;24(Suppl 5). Search in Google Scholar

40. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87–96. 10.1016/S0021-9150(00)00468-8Search in Google Scholar

41. Sumi D, Hayashi T, Thankur NK, Jayachandran M, Asai Y, Kano H, et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects — the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001; 155: 347–57. 10.1016/S0021-9150(00)00597-9Search in Google Scholar

42. Yasuhara M, Suzumura K, Tankaka K, Takahashi M, Aoki S, Odawara A, et al. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits. Biol Pharm Bull 2000; 23: 570–4. 10.1248/bpb.23.570Search in Google Scholar

43. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochem Biophys Acta 1993; 1165: 335–8. 10.1016/0005-2760(93)90145-YSearch in Google Scholar

44. Inoue T, Hayashi M, Takayanagi K, Morooka S. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis 2002; 160: 369–76. 10.1016/S0021-9150(01)00585-8Search in Google Scholar

45. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403–25. Search in Google Scholar

46. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J Am Med Assoc 1990; 264: 71–5. 10.1001/jama.1990.03450010075034Search in Google Scholar

47. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80: 106–7. 10.1016/S0002-9149(97)00298-1Search in Google Scholar

48. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601–10. Search in Google Scholar

49. Gaddi A, Arca M, Ciarrocchi A, Fazio S, D'Alo G, Tiozzo R, et al. Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts. Metabolism 1991; 40: 1074–8. 10.1016/0026-0495(91)90132-GSearch in Google Scholar

50. Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer BE, van den Ende A, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996; 39: 867–71. 10.1203/00006450-199605000-00021Search in Google Scholar

51. Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson M, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. J Am Med Assoc 1999; 281: 137–44. 10.1001/jama.281.2.137Search in Google Scholar

52. Koizumi J, Haraki T, Yagi K, Inazu A, Kajinami K, Miyamoto S, et al. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia. Am J Cardiol 1995; 76: 47A–50A. 10.1016/S0002-9149(05)80016-5Search in Google Scholar

53. de Sauvage Nolting PR, Buirma RJ, Hutten BA, Kastelein JJ, Dutch ExPRESS Investigator Group. Two-year efficacy and safety of simvastatin 80mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]). Am J Cardiol 2002; 90: 181–4. 10.1016/S0002-9149(02)02449-9Search in Google Scholar

54. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 1527–31. 10.1161/01.ATV.17.8.1527Search in Google Scholar

55. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: 66B–69B. 10.1016/S0002-9149(98)00041-1Search in Google Scholar

56. Lind S, Olsson AG, Eriksson M, Rudling M, Eggertsen G, Angelin B. Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med 2004; 256: 406–12. 10.1111/j.1365-2796.2004.01401.xSearch in Google Scholar PubMed

57. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152–60. 10.1016/S0002-9149(03)00530-7Search in Google Scholar

58. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Comparison of therapy with simvastatin 80mg and atorvastatin 80mg in patients with familial hypercholesterolaemia. Int J Clin Pract 1999; 53: 609–11. Search in Google Scholar

59. Fieseler HG, Armstrong VW, Wieland E, Thiery J, Schutz E, Walli AK, et al. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor pravastatin: results of a 2-year investigation. Clin Chim Acta 1991; 204: 291–300. 10.1016/0009-8981(91)90239-9Search in Google Scholar

60. Simons LA, Nestel PJ, Clifton P, Janus ED, Simons J, Parfitt A. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years. Med J Aust 1992; 157: 584–9. 10.5694/j.1326-5377.1992.tb137395.xSearch in Google Scholar

61. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, et al. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993; 87: III35–44. Search in Google Scholar

62. Brorholt-Petersen JU, Jensen HK, Raungaard B, Gregersen N, Faergeman O. LDL-receptor gene mutations and the hypocholesterolemic response to statin therapy. Clin Genet 2001; 59: 397–405. 10.1034/j.1399-0004.2001.590604.xSearch in Google Scholar

63. Sijbrands EJ, Lombardi MP, Westendorp RG, Leuven JA, Meinders AE, Van der Laarse A, et al. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 1998; 136: 247–54. 10.1016/S0021-9150(97)00216-5Search in Google Scholar

64. Vohl MC, Szots F, Lelievre M, Lupien PJ, Bergeron J, Gagne C, et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 2002; 160: 361–8. 10.1016/S0021-9150(01)00584-6Search in Google Scholar

65. Couture P, Brun LD, Szots F, Lelievre M, Gaudet D, Despres JP, et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998; 18: 1007–12. 10.1161/01.ATV.18.6.1007Search in Google Scholar

66. Chaves FJ, Real JT, Garcia-Garcia AB, Civera M, Armengod ME, Ascaso JF, et al. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. J Clin Endocrinol Metab 2001; 86: 4926–32. 10.1210/jcem.86.10.7899Search in Google Scholar

67. Jeenah M, September W, Graadt van Roggen F, de Villiers W, Seftel H, Marais D. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1993; 98: 51–8. 10.1016/0021-9150(93)90222-GSearch in Google Scholar

68. Sun XM, Patel DD, Knight BL, Soutar AK. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group. Atherosclerosis 1998; 136: 175–85. 10.1016/S0021-9150(97)00181-0Search in Google Scholar

69. Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1999; 143: 41–54. 10.1016/S0021-9150(98)00274-3Search in Google Scholar

70. Vuorio AF, Ojala JP, Sarna S, Turtola H, Tikkanen MJ, Kontula K. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. J Intern Med 1995; 237: 43–8. 10.1111/j.1365-2796.1995.tb01138.xSearch in Google Scholar

71. Leren TP, Hjermann I. Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene? Eur J Clin Invest 1995; 25: 967–73. 10.1111/j.1365-2362.1995.tb01975.xSearch in Google Scholar

72. Kajinami K, Yagi K, Higashikata T, Inazu A, Koizumi J, Mabuchi H. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am J Cardiol 1998; 82: 113–7. 10.1016/S0002-9149(98)00230-6Search in Google Scholar

73. Civeira F. International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173: 55–68. 10.1016/j.atherosclerosis.2003.11.010Search in Google Scholar PubMed